V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310009970 | 310005552 | 1.72 | 65.1 | Adjuvant (A) | 2017-01-22 | 2017-02-05 | GEMCITABINE + VINORELBINE | 02 | N | 310016444 | DACARBAZINE |
| 310009971 | 310005557 | 1.7 | 71 | Palliative (P) | 2018-11-19 | 2019-03-05 | TRASTUZUMAB | 02 | N | 310018382 | AXITINIB |
| 310009972 | 310005559 | 1.6 | 54.8 | Curative (C) | 2017-12-11 | 2017-12-18 | Methotrexate High Dose (3g/m2) | null | N | 310018395 | DOXORUBICIN |
| 310009973 | 310005564 | 1.58 | 23.6 | Palliative (P) | 2016-12-30 | 2016-12-30 | ICON8B TRIAL | N | N | 310018837 | DOXORUBICIN + IFOSFAMIDE + VINCRISTINE |
| 310009974 | 310005567 | 1.6 | null | Curative (C) | 2014-09-22 | 2014-09-25 | Ifosfamide | N | null | 310019072 | AZACITIDINE |
| 310009975 | 310005570 | 1.83 | 72.8 | Curative (C) | 2018-08-09 | 2018-10-01 | ECX | 2 | N | 310020027 | CEV |
| 310009976 | 310005571 | 1.77 | 64.9 | Palliative (P) | 2016-10-25 | 2016-12-09 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | N | N | 310020428 | IRINOTECAN + MDG |
| 310009977 | 310011338 | null | 59.7 | Palliative (P) | 2016-11-28 | 2016-11-28 | Doxorubicin + Olaratumab | N | N | 310020916 | CAPECITABINE |
| 310009978 | 310005573 | 0 | 64.5 | Curative (C) | 2017-05-22 | 2017-09-26 | Trastuzumab Subcutaneous | null | null | 310021204 | TOPOTECAN |
| 310009979 | 310005574 | null | 106.7 | Adjuvant (A) | 2015-02-23 | 2015-02-24 | CTD (Thalidomide 200mg) | N | N | 310021296 | OXALIPLATIN + MDG |
| 310009980 | 310008473 | null | 61.1 | Palliative (P) | 2017-02-14 | 2017-06-06 | Trabectedin | N | N | 310021471 | ICON8B TRIAL |
| 310009981 | 310005579 | 1.77 | null | Neo-adjuvant (N) | 2014-10-06 | 2014-11-17 | ECX | N | N | 310021589 | CHLORAMBUCIL |
| 310009982 | 310008477 | 0 | 59.9 | Palliative (P) | null | 2016-02-07 | FLUOROURACIL + IRINOTECAN | null | Y | 310021779 | RMS 2005 TRIAL |
| 310009983 | 310008477 | 1.7 | 81 | Curative (C) | 2017-10-01 | 2017-10-09 | CYCLO + ETOPOSIDE + NELARABINE | N | null | 310021779 | HYDROXYCARBAMIDE |
| 310009984 | 310005585 | null | null | Palliative (P) | 2015-08-27 | 2015-12-17 | EW EuroEwing 2012 Arm A VIDE | N | N | 310022160 | BORTEZOMIB |
| 310009985 | 310008479 | null | null | Disease modification (D) | 2018-12-25 | 2019-01-01 | EOX | 02 | null | 310022335 | VEMURAFENIB |
| 310009986 | 310005588 | 1.73 | null | null | 2015-09-09 | 2017-07-14 | Vemurafenib | 2 | null | 310022506 | METHOTREXATE HIGH DOSE |
| 310009987 | 310005590 | 1.6 | 74.6 | Palliative (P) | 2014-06-08 | 2014-06-08 | IPILIMUMAB + NIVOLUMAB | N | N | 310022528 | LANREOTIDE |
| 310009988 | 310005591 | 0 | 72.6 | Curative (C) | 2014-10-26 | 2014-10-28 | ALL UKALL2011 TRIAL | 2 | N | 310022562 | EOX |
| 310009989 | 310005594 | 1.57 | 0 | Palliative (P) | 2014-10-05 | 2014-10-05 | FLUOROURACIL + MITOMYCIN | N | N | 310022639 | CISPLATIN + ETOPOSIDE |
| 310009990 | 310008486 | null | 81 | Curative (C) | 2015-02-22 | 2015-08-09 | IVADo | 02 | null | 310022751 | IRINOTECAN |
| 310009991 | 310005598 | 1.65 | 96.4 | Curative (C) | 2014-05-29 | 2014-07-05 | Temozolomide 200mg/m2 | 02 | N | 310022751 | VEMURAFENIB |
| 310009992 | 310008488 | 1.89 | 23.6 | Palliative (P) | 2017-03-02 | 2017-03-10 | Fludarabine + Melphalan RIC Allo | null | null | 310022786 | ECX |
| 310009993 | 310005602 | 1.67 | 92.2 | null | 2019-04-04 | 2019-04-04 | METHOTREXATE | 2 | N | 310022819 | NIVOLUMAB |
| 310009994 | 310008490 | 1.85 | 74.5 | Palliative (P) | 2017-03-09 | 2017-04-01 | Trastuzumab 21 day loading dose | Y | N | 310022826 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE |
| 310009995 | 310005605 | null | 73 | Curative (C) | 2015-01-24 | 2018-11-19 | IVE + METHOTREXATE | N | N | 310022924 | TRASTUZUMAB |
| 310009996 | 310005608 | null | 82.9 | Palliative (P) | 2017-03-01 | 2017-03-04 | Alemtuzumab | N | N | 310022924 | BCG |
| 310009997 | 310011604 | 1.67 | null | Curative (C) | 2018-05-26 | 2018-05-28 | Lenalidomide Cycle 26 onwards (PAS) | 02 | N | 310022984 | TRASTUZUMAB |
| 310009998 | 310011343 | 1.83 | null | Palliative (P) | 2019-01-04 | 2019-09-16 | CHOEP | 2 | null | 310023035 | BCG |
| 310009999 | 310005611 | 1.62 | 72.4 | Palliative (P) | 2018-05-17 | 2018-05-22 | Bendamustine + prednisolone | 02 | N | 310023035 | TRASTUZUMAB |
| 310010000 | 310008494 | 1.74 | 79.3 | null | null | 2015-12-05 | RCEOP | 99 | null | 310023055 | ALEMTUZUMAB |
| 310010001 | 310005613 | 1.63 | null | Palliative (P) | 2017-10-01 | 2017-10-09 | Hydroxycarbamide | N | N | 310023141 | TRASTUZUMAB |
| 310010002 | 310005614 | 1.77 | 25.8 | Palliative (P) | 2017-02-21 | 2017-02-26 | ICE + GCSF | N | N | 310023219 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 310010003 | 310005614 | 1.79 | 50.3 | Adjuvant (A) | 2014-01-03 | 2014-02-18 | Capecitabine | 02 | N | 310023219 | TRASTUZUMAB |
| 310010004 | 310011906 | 1.79 | null | Curative (C) | 2018-03-25 | 2018-03-31 | Alemtuzumab | 2 | null | 310023378 | ADE |
| 310010005 | 310011936 | null | 62 | Palliative (P) | 2017-08-30 | 2017-09-09 | TRASTUZUMAB | N | null | 310023406 | OXALIPLATIN + MDG |
| 310010006 | 310005615 | 1.81 | 113.8 | Curative (C) | 2015-10-29 | 2015-11-01 | CHOP R + METHOTREXATE | 02 | N | 310023408 | ECHELON-2 TRIAL |
| 310010007 | 310010034 | 1.63 | 64.7 | Curative (C) | null | 2014-10-10 | CYCLO + RITUXIMAB + VINCRISTINE | N | N | 310023408 | CAPECITABINE + OXALIPLATIN |
| 310010008 | 310005621 | 1.7 | 48.6 | Palliative (P) | 2017-03-26 | 2017-03-29 | Cisplatin + Paclitaxel | N | Y | 310023655 | DHAP - R |
| 310010009 | 310005625 | null | 63.9 | null | 2016-11-20 | 2017-05-12 | Cetuximab 14 day | 02 | N | 310023689 | NIVOLUMAB |
| 310010010 | 310005626 | 1.8 | 47.6 | Palliative (P) | 2015-07-03 | 2015-07-31 | STS Rhabdomyosarcoma RMS 2005 IVA | N | N | 310023699 | CARBOPLATIN + RT |
| 310010011 | 310005628 | 1.8 | 63.9 | Curative (C) | 2014-09-25 | 2015-12-17 | EVEROLIMUS | 02 | N | 310023716 | CAPECITABINE |
| 310010012 | 310005629 | 1.85 | 60.5 | Palliative (P) | 2016-10-21 | 2016-11-17 | Alemtuzumab cond (RI ALLO CAMP100) | 2 | N | 310023810 | ICE |
| 310010013 | 310011346 | 1.6 | 76 | Palliative (P) | 2017-04-13 | 2017-04-20 | Lenalidomide Cycle 26 onwards (PAS) | N | null | 310023870 | DABRAFENIB + TRAMETINIB |
| 310010014 | 310005633 | 1.57 | null | Adjuvant (A) | 2015-10-01 | 2018-12-03 | Cetuximab 7 day (>Cycle 2) | N | N | 310024116 | TEMOZOLOMIDE |
| 310010015 | 310005635 | 1.57 | null | Adjuvant (A) | 2017-03-07 | 2017-03-07 | VINCRISTINE | null | N | 310024235 | ICON TRIAL |
| 310010016 | 310005637 | 1.8 | 58.6 | Curative (C) | 2018-02-06 | 2018-02-15 | DOXORUBICIN | N | N | 310024263 | DABRAFENIB |
| 310010017 | 310008509 | 1.85 | 93.7 | Curative (C) | 2016-02-27 | 2016-02-27 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 310024307 | GEMCITABINE + VINORELBINE |
| 310010018 | 310005642 | 1.74 | 0 | Palliative (P) | 2014-03-03 | 2014-04-21 | Carboplatin + Pemetrexed | N | N | 310024340 | IRINOTECAN |
| 310010019 | 310010040 | 1.82 | null | Adjuvant (A) | 2016-09-07 | 2017-01-05 | CISPLATIN + DACTINOMYCIN + ETOPOSIDE + METHOTREXATE | N | N | 310024417 | OXALIPLATIN + MDG |